Citations

Clear

904 citation(s) found for "Gordon, S".

The Authors’ Reply
Travis, Lois B. , Pierre, Robert V., Dewald, Gordon W.

Mayo Clinic

American Journal of Clinical Pathology | March 17, 2016 | Volume: 86 | Issue: 1 | Pages: 128-129

10.1093/ajcp/86.1.128a Get It

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Dimopoulos, Meletios Α. , Sonneveld, Pieter , Merlini, Giampaolo , Kastritis, Efstathios , Goldschmidt, Hartmut , Joshua, Douglas, Orlowski, Robert Z. , Powles, Raymond, Vesole, David H., Garderet, Laurent, Palumbo, Antonio , Cavo, Michèle , Richardson, Paul G. , Moreau, Philippe , Miguel, Jesús F. San , Durie, Brian G.M. , Terpos, Evangelos , Bergsagel, P. Leif , Russell, Stephen J. , Rosiñol, Laura , Ocio, Enrique M. , García‐Sánz, Ramón , Beksaç, Meral , Zweegman, Sonja , Usmani, Saad Z. , Donk, Niels W.C.J. van de , Pratt, Guy , Chari, Ajai , Cook, Gordon , Rossi, Adriana , O’Dwyer, Michael , Paiva, Bruno , Larrea, Carlos Fernández de , Souza, Cármino Antônio De , Terragna, Carolina , Bergsagel, P. Leif , Dimopoulos, Meletios A, Ludwig, Heinz , San Miguel, Jesús, Leung, Nelson , Joshua, Douglas, Orlowski, Robert Z. , Einsele, Hermann , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Zweegman, Sonja , Merlini, Giampaolo , Dimopoulos, Meletios A , Russell, Stephen J , Moreau, Philippe , Terpos, Evangelos , Chari, Ajai , San-Miguel, Jesus , Paiva, Bruno , Kastritis, Efstathios , Garcia-Sanz, Ramon , Beksac, Meral , Cook, Gordon , Usmani, Saad , Rossi, Adriana , Ocio, Enrique M

Mayo Clinic

Journal of Clinical Oncology | March 14, 2016 | Volume: 34 | Issue: 13 | Pages: 1544-1557

10.1200/jco.2015.65.0044 | PMID 26976420 Get It

Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m 2 to 140 mg/m 2 ) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network
Crosslin, DR, Owusu‐Obeng, Aniwaa, Wallace, John R. , Almoguera, Berta , Basford, MA, Bielinski, Suzette J. , Carrell, DS, Connolly, John J. , Doheny, KF, Gallego, CJ, Gordon, Allan , Kirby, Jacqueline, Kitchner, Terrie, Manzi, Shannon , Mejia, A R, Pan, Vivian , Perry, Cassandra, Peterson, JF, Prows, CA, Ralston, James D. , Scott, Stuart A. , Scrol, Aaron, Smith, Maureen E. , Stallings, SC, Veldhuizen, Tamra L., Wolf, W.A., Volpi, Simona , Wiley, Kenneth L , Manolio, Teri A. , Böttinger, Erwin P. , Brilliant, MH, Carey, David J. , Chisholm, Rex L. , Chute, CG, Jl, Haines, Håkonarson, Håkon , Harley, JB, Holm, Ingrid A. , Kullo, IJ, Jarvik, GP, Larson, EB, McCarty, Catherine A. , Williams, MS, Denny, Joshua C. , Rasmussen‐Torvik, LJ, Roden, DM, Ritchie, MD, Rasmussen‐Torvik, Laura J. , Jarvik, Gail P. , Peterson, Josh F. , Bush, William S. , Wallace, J, Crawford, Dana C. , Keating, Brendan J. , Perry, CL, Peterson, JF, Stallings, SC, Li, R, Roden, DM, Ritchie, M.D., Holm, Ingrid A , Hakonarson, Hakon , Denny, Joshua C , Jarvik, Gail P , Bielinski, Suzette , Gordon, Adam S , Connolly, John J , Peterson, Josh F , Scott, Stuart A , Rasmussen-Torvik, Laura J

Mayo Clinic

Clinical Pharmacology & Therapeutics | February 9, 2016 | Volume: 100 | Issue: 2 | Pages: 160-169

10.1002/cpt.350 | PMID 26857349 Get It

Genetic variation can affect drug response in multiple ways, although it remains unclear how rare genetic variants affect drug response. The electronic Medical Records and Genomics (eMERGE) Network, collaborating with the Pharmacogenomics Research Network, began eMERGE‐PGx, a targeted sequencing study to assess genetic variation in 82 pharmacogenes critical for implementation of “precision medicine.” The February 2015 eMERGE‐PGx data release includes sequence‐derived data from ∼5,000 clinical subjects. We present the variant frequency spectrum categorized by variant type, ancestry, and predicted function. We found 95.12% of genes have variants with a scaled Combined Annotation‐Dependent Depletion score above 20, and 96.19% of all samples had one or more Clinical Pharmacogenetics Implementation Consortium Level A actionable variants. These data highlight the distribution and scope of genetic variation in relevant pharmacogenes, identifying challenges associated with implementing clinical sequencing for drug treatment at a broader level, underscoring the importance for multifaceted research in the execution of precision medicine.
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays
Hoofnagle, Andrew N. , Carr, Steven A. , Liu, Tao , Massoni, Sam A., Thomas, Stefani N. , Townsend, R. Reid , Zimmerman, Lisa J. , Boja, Emily S. , Chen, Jing , Crimmins, Daniel L., Davies, Sherri R. , Hiltke, Tara , Ketchum, Karen A. , Kinsinger, Christopher R. , Mesri, Mehdi , Meyer, Matthew R. , Qian, Weijun , Schoenherr, Regine M., Scott, Mitchell G., Shi, Tujin , Whiteley, Gordon , Wrobel, John A. , Wu, Chaochao, Ackermann, Brad, Barnidge, David R. , Bunk, David M. , Clarke, Nigel J. , Fishman, Jordan B., Grant, Russ P., Kushnir, Mark M. , Lowenthal, Mark S. , Neubert, Hendrik , Patterson, Scott D. , Rockwood, Alan L. , Rogers, John , Eyk, Jennifer E. Van , Wong, Steven, Zhang, Shucha, Chan, Daniel W. , Chen, Xian , Liebler, D.C. , Rodland, Karin , Rodriguez, Henry , Paulovich, Amanda G. , Whiteaker, Jeffrey R. , Kuhn, Eric W. , Gao, Yuqian , Aebersold, Ruedi , Grant, Russell P. , Kusebauch, Ulrike , Moritz, Robert L. , Singh, Ravinder J. , Ellis, Matthew J. , Smith, Richard , Zhang, Zhen , Zhang, Hui , Davies, S. J.

Mayo Clinic

Clinical Chemistry | December 30, 2015 | Volume: 62 | Issue: 1 | Pages: 48-69

10.1373/clinchem.2015.250563 | PMID 26719571 Get It

AbstractBACKGROUNDFor many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now beginning to deploy these work flows as well. For assays that use proteolysis to generate peptides for protein quantification and characterization, synthetic stable isotope–labeled internal standard peptides are of central importance. No general recommendations are currently available surrounding the use of peptides in protein mass spectrometric assays.CONTENTThe Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute has collaborated with clinical laboratorians, peptide manufacturers, metrologists, representatives of the pharmaceutical industry, and other professionals to develop a consensus set of recommendations for peptide procurement, characterization, storage, and handling, as well as approaches to the interpretation of the data generated by mass spectrometric protein assays. Additionally, the importance of carefully characterized reference materials—in particular, peptide standards for the improved concordance of amino acid analysis methods across the industry—is highlighted. The alignment of practices around the use of peptides and the transparency of sample preparation protocols should allow for the harmonization of peptide and protein quantification in research and clinical care.
Response to treatment in a prospective national infantile spasms cohort
Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Leister, Erin, Loddenkemper, Tobias , Grinspan, Zachary M. , Hartman, Adam L. , Kossoff, Eric H. , Gaillard, William D. , Mytinger, John R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Sullivan, Joseph , Dlugos, Dennis , Hamikawa, Lorie, Berg, Anne T. , Millichap, J Gordon , Knupp, Kelly G. , Nordli, Douglas R. , Wirrell, Elaine , Millichap, John , Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason

Mayo Clinic

Annals of Neurology | December 24, 2015 | Volume: 79 | Issue: 3 | Pages: 475-484

10.1002/ana.24594 | PMID 26704170 Get It

ObjectiveInfantile spasms are seizures associated with a severe epileptic encephalopathy presenting in the first 2 years of life, and optimal treatment continues to be debated. This study evaluates early and sustained response to initial treatments and addresses both clinical remission and electrographic resolution of hypsarrhythmia. Secondarily, it assesses whether response to treatment differs by etiology or developmental status.MethodsThe National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of infantile spasms. Children were considered responders if there was clinical remission and resolution of hypsarrhythmia that was sustained at 3 months after first treatment initiation. Standard treatments of adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin were considered individually, and all other nonstandard therapies were analyzed collectively. Developmental status and etiology were assessed. We compared response rates by treatment group using chi‐square tests and multivariate logistic regression models.ResultsTwo hundred thirty infants were enrolled from 22 centers. Overall, 46% of children receiving standard therapy responded, compared to only 9% who responded to nonstandard therapy (p < 0.001). Fifty‐five percent of infants receiving ACTH as initial treatment responded, compared to 39% for oral corticosteroids, 36% for vigabatrin, and 9% for other (p < 0.001). Neither etiology nor development significantly modified the response pattern by treatment group.InterpretationResponse rate varies by treatment choice. Standard therapies should be considered as initial treatment for infantile spasms, including those with impaired development or known structural or genetic/metabolic etiology. ACTH appeared to be more effective than other standard therapies. ANN NEUROL 2016;79:475–484
O2‐01‐03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence
Tang, Mengxuan , Owen, Christopher J. , Su, Yi , Hornbeck, Russ C. , Stevenson, Trish A., Cash, Lisa, Raichle, Marcus E., Preboske, Gregory M., Xiong, Chengjie , Moulder, Krista L., Buckles, Virginia, Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , Raichle, Marcus E. , Gordon, Brian A. , Koeppe, Robert A. , Jack, Clifford R. , Goate, Alison , Cruchaga, Carlos , Bateman, Randall J. , Morris, John C. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2015.07.132 Get It

IC‐P‐051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence
Tang, Mengxuan , Owen, Christopher J. , Hornbeck, Russ C. , Stevenson, Trish A., Cash, Lisa, Raichle, Marcus E. , Preboske, Gregory M., Xiong, Chengjie , Moulder, Krista L., Buckles, Virginia, Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , Su, Yi , Gordon, Brian A. , Koeppe, Robert A. , Jack, Clifford R. , Goate, Alison , Cruchaga, Carlos , Bateman, Randall J. , Morris, John C. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2015.06.072 Get It

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
Burns, Ted M., Smith, Gordon, Allen, Jeffrey A. , Amato, Anthony A. , Arnold, W. David , Barohn, Richard J., Benatar, Michael , Bird, Shawn J. , Bromberg, Mark B. , Chahin, Nizar, Ciafaloni, Emma , Corse, Andrea M. , David, William S., Dimberg, Elliot L., Sousa, De , Donofrio, Peter D., Dyck, P. James B. , Engel, Andrew G. , Ensrud, Erik , Ferrante, Mark A., Freimer, Miriam , Gable, Karissa , Gibson, Summer, Gilchrist, James M. , Goldstein, Jonathan , Gooch, Clifton L. , Goodman, Brent P., Gorelov, Dmitri, Gospe, Sídney M. , Goyal, Namita , Guidon, Amanda C. , Guptill, Jeffrey T. , Gutmann, Laurie , Gutmann, Ludwig , Gwathmey, Kelly , Harati, Yadollah, Harper, C. Michel , Hehir, Michael K. , Hobson‐Webb, Lisa D., Howard, James F. , Jackson, Carlayne E. , Jones, Sarah , Juel, Vern C. , Kaminski, Henry J. , Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah , Lacomis, David , Larriviere, Daniel G., Lewis, Richard A. , Litchy, William J. , Logigian, Eric L. , Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo A. , Massey, Janice M., Mauermann, Michelle L. , Mathews, Katherine D. , Meriggioli, Matthew N. , Moon, Joon-Shik, Mozaffar, Tahseen , Nations, Sharon , Ostrow, Lyle W. , Pascuzzi, Robert M. , Peltier, Amanda , Ruzhansky, Katherine , Ross, Mark A., Rubin, Devon I., Russell, James A., Sachs, George, Salajegheh, Mohammad, Saperstein, David , Scelsa, Stephen N. , Selcen, Duygu , Shaibani, Aziz , Silvestri, Nicholas J. , Singleton, J. Rob, Smith, Benn E., So, Yuen T., Solórzano, Guillermo, Sorenson, Eric J. , Srinivasen, Jayashri, Tavee, Jinny , Tawil, Rabi , Thaisetthawatkul, Pariwat , Thornton, Charles A. , Trivedi, Jaya , Vernino, Steven , Wang, Annabel K., Webb, Tyler A., Weiss, Michael D. , Windebank, Anthony J. , Wolfe, Gil I. , Crum, Brian A. , Dimberg, Elliot, Chahin, Nizar, Cohen, Jeffrey Allen , Johnson, Nicholas E , Karam, Chafic , Ladha, Shafeeq , Li, Yuebing , Miller, Robert G. , Nowak, Richard J. , Richman, David P. , Shieh, Perry B. , Kolb, Noah A , Mauermann, Michelle L , Gutmann, Laurie , Allen, Jeffrey A , Arnold, W David , Vernino, Steven , Kaminski, Henry

Mayo Clinic

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952 Get It

Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study
Miller, Virginia M. , Jenkins, Gregory D. , Heit, John A. , Huggins, Gordon S. , Hodis, Howard N., Budoff, Matthew J. , Løbo, Rogerio A. , Taylor, Hugh S. , Black, Dennis M. , Harman, S. Mitchell , de Andrade, Mariza, Biernacka, Joanna M. , Manson, JoAnn E. , Naftolin, Frederick , Andrade, Mariza de , Budoff, Matthew

Mayo Clinic

Physiological Genomics | October 28, 2015 | Volume: 48 | Issue: 1 | Pages: 33-41

10.1152/physiolgenomics.00029.2015 | PMID 26508701 Get It

Prior to the initiation of menopausal hormone treatment (MHT), genetic variations in the innate immunity pathway were found to be associated with carotid artery intima-medial thickness (CIMT) and coronary arterial calcification (CAC) in women ( n = 606) enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Whether MHT might affect these associations is unknown. The association of treatment outcomes with variation in the same 764 candidate genes was evaluated in the same KEEPS participants 4 yr after randomization to either oral conjugated equine estrogens (0.45 mg/day), transdermal 17β-estradiol (50 μg/day), each with progesterone (200 mg/day) for 12 days each month, or placebo pills and patch. Twenty SNPs within the innate immunity pathway most related with CIMT after 4 yr were not among those associated with CIMT prior to MHT. In 403 women who completed the study in their assigned treatment group, single nucleotide polymorphisms (SNPs) within the innate immunity pathway were found to alter the treatment effect on 4 yr change in CIMT (i.e., significant interaction between treatment and genetic variation in the innate immunity pathway; P < 0.001). No SNPs by treatment effects were observed with changes of CAC >5 Agatston units after 4 yr. Results of this study suggest that hormonal status may interact with genetic variants to influence cardiovascular phenotypes, specifically, the pharmacogenomic effects within the innate immunity pathway for CIMT.